Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30573% above fair value
$220.83−0.89 (-0.40%)
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna AstraZeneca collaboration revenue by Year
AstraZeneca collaboration revenue ($M) ($M)
Moderna AstraZeneca collaboration revenue: $0M in FY2024. No newer figure appears in the documents we track.
Latest, FY2024
0
Period ended Dec 31, 2024
Change on a year earlier
–
0 in FY2023
History
7 years
Since FY2018
Sources
5
Documents cited below
Where the FY2024 figure comes from
Source: Form 10-K (filed 2025-02-21) ↗
Reported in Form 10-Q / 10-K Collaboration Agreements Note.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | AstraZeneca collaboration revenue ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | – | Form 10-K (filed 2025-02-21) ↗ |
| FY2023 | Dec 31, 2023 | 0 | -100.0% | Form 10-K (filed 2025-02-21) ↗ |
| FY2022 | Dec 31, 2022 | 80 | +1,042.9% | Form 10-K (filed 2025-02-21) ↗ |
| FY2021 | Dec 31, 2021 | 7 | -78.8% | Form 10-K (filed 2024-02-23) ↗ |
| FY2020 | Dec 31, 2020 | 33 | +560.0% | Form 10-K (filed 2023-02-24) ↗ |
| FY2019 | Dec 31, 2019 | 5 | -89.1% | Form 10-K (filed 2022-02-25) ↗ |
| FY2018 | Dec 31, 2018 | 46 | – | Form 10-K (filed 2019-03-13) ↗ |
Cite this data
StockData. (2026). Moderna AstraZeneca collaboration revenue ($M), annual FY2018–FY2024 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/rev-collab-az
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.